Annexon Announces Positive Topline Results From Real-World Evidence Study Comparing Anx005 Treatment to Intravenous Immunoglobulin (Ivig) or Plasma Exchange (Pe) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (Gbs)
Annexon宣佈關於真實世界證據研究的積極頂線結果，該研究比較了Anx005治療與靜脈注射免疫球蛋白(Ivig)或血漿置換(市盈率)在格林-巴利綜合症(Gbs)治療中的效果，研究對象爲匹配患者群體。